CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 77,3% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär Gilead GILD

Sälj
 Köp

Gilead realtidsdiagram

5m 15m 30m 1h 4h 1d 1w

Instrumentfundament

Weekly Search
Weekly
Daily
Datum Stäng Förändring Förändring (%) Öppna Hög Låg

Gilead news

Frances Wang 2024 Aug 04, 16:00

The Week Ahead: ISM services, SMCI

CFD Trading
Magnificent Seven earnings take centre stage in the markets this week
Neil Wilson 2024 Apr 19, 01:00

Week ahead: Wall Street’s Magnificent Seven earnings are up

Commodities Forex Indices Shares
Disney is catching up with Netflix
Neil Wilson 2024 Feb 01, 08:03

Week ahead: Earnings season climax

Forex Indices
Consumer inflation
Neil Wilson 2023 Nov 03, 04:01

Week ahead: RBA poised to hike?

Forex Indices
Megacap-tech-stocks.jpg
Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

Senaste nyheter

Visa mer
Frances Wang 2025 Maj 12, 16:00

ADA crypto price forecast: What factors influence the price of Cardano?

Cryptocurrencies
Tommy Yap 2025 Maj 12, 16:00

Morning Note: Tariff Rollback Sparks Stock Rally; US CPI Watch; Bailey's Speech

Morning Note Equities
Tommy Yap 2025 Maj 12, 04:00

Morning Note: US Surplus Expected; Denmark Inflation; UK Retail Sales Forecast

Morning Note EUR
Frances Wang 2025 Maj 11, 16:00

How the US-China Trade War Influenced Global Commodity Markets?

Commodities
Tommy Yap 2025 Maj 09, 21:00

Week Ahead: U.S. Inflation Data in Spotlight

Forex Indices
Frances Wang 2025 Maj 08, 16:00

What Is Happening to the Bond Market: Bond Market Outlook 2025

Bonds
Frances Wang 2025 Maj 08, 16:00

Bond Market News Today: Alphabet (GOOGL) Back to Corporate Bond Market

Bonds
Frances Wang 2025 Maj 08, 16:00

Tariffs News Update: How Trump’s Policies Affect Bond Market?

Bonds

Info

Spread

0.61

Spread (%)

0.6024 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaderna är stängda

Onsdag

13:31 - 19:59

Måndag

13:31-19:59

Tisdag

13:31-19:59

Torsdag

13:31-19:59

Fredag

13:31-19:59

Analys och statistik

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

126280343552

Utelöpande aktier

1244999936

Rapportdatum (nästa)

2013-01-28

Utd-procent

2025-06-27

Datum efter utdelning

2025-06-13

Förväntad framtida årlig utdelningsprocent

3.16

Förväntad framtida årlig direktavkastning

0.0304

Vinst per aktie

4.75

Läs mer om detta instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)

Handla nu

Handla nu

Handla nu

Handla nu
Relaterade instrument

latest_education_articles

Visa mer
Trustpilot